

Jinyan Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7422103/publications.pdf>

Version: 2024-02-01

44
papers

9,010
citations

126858

33
h-index

223716

46
g-index

52
all docs

52
docs citations

52
times ranked

13510
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995
2	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.	6.0	978
3	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
4	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
5	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. <i>Nature</i> , 2014, 512, 74-77.	13.7	527
6	Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. <i>Nature</i> , 2009, 457, 87-91.	13.7	433
7	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 603, 493-496.	13.7	326
8	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	3.8	307
9	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	6.0	303
10	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
11	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	6.6	286
12	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
13	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nature Medicine</i> , 2021, 27, 515-525.	15.2	248
14	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	13.7	246
15	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018, 563, 360-364.	13.7	246
16	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2021, 385, 2010-2012.	13.9	228
17	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVS Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 951-953.	13.9	192
18	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. <i>Cell</i> , 2017, 169, 610-620.e14.	13.5	191

#	ARTICLE	IF	CITATIONS
19	Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. <i>Cell</i> , 2016, 165, 656-667.	13.5	144
20	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. <i>Science</i> , 2016, 353, 1045-1049.	6.0	129
21	Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys. <i>Journal of Virology</i> , 2010, 84, 10406-10412.	1.5	120
22	Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys. <i>Journal of Virology</i> , 2008, 82, 4844-4852.	1.5	113
23	Recruitment of Antigen-Presenting Cells to the Site of Inoculation and Augmentation of Human Immunodeficiency Virus Type 1 DNA Vaccine Immunogenicity by In Vivo Electroporation. <i>Journal of Virology</i> , 2008, 82, 5643-5649.	1.5	111
24	Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 248-256.	1.9	98
25	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	13.7	71
26	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. <i>Nature Medicine</i> , 2020, 26, 228-235.	15.2	61
27	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
28	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. <i>Science Translational Medicine</i> , 2022, 14, eabn6150.	5.8	57
29	Modulation of DNA Vaccine-Elicited CD8 + T-Lymphocyte Epitope Immunodominance Hierarchies. <i>Journal of Virology</i> , 2006, 80, 11991-11997.	1.5	55
30	Low-dose Ad26.COVS protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49
31	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. <i>Annals of Internal Medicine</i> , 2021, 174, 585-594.	2.0	44
32	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
33	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
34	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39
35	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641.	5.8	15
36	Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. <i>Journal of Infectious Diseases</i> , 2022, 225, 1124-1128.	1.9	15

#	ARTICLE	IF	CITATIONS
37	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
38	A homologous or variant booster vaccine after Ad26.COVID.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
39	Accelerated Heterologous Adenovirus Prime-Boost SIV Vaccine in Neonatal Rhesus Monkeys. <i>Journal of Virology</i> , 2012, 86, 7829-7835.	1.5	12
40	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , 2021, 95, e0097421.	1.5	12
41	Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation. <i>Nature Communications</i> , 2020, 11, 5412.	5.8	9
42	Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics. <i>Scientific Reports</i> , 2021, 11, 15295.	1.6	5
43	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2022, 96, JVI0159921.	1.5	5
44	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. <i>Npj Vaccines</i> , 2022, 7, 53.	2.9	4